The biosensor developer has closed the final tranche of a series C round co-led by Baxter International's corporate venturing unit.
VitalConnect, a US-based biosensor system developer, has closed a $38m series C round co-led by Baxter Ventures, the corporate venture capital arm of medical products manufacturer Baxter International.
The round was raised across four tranches, the final tranche adding $5m to the $33m VitalConnect had raised as of May 2017. Private equity firm MVM Life Science Partners co-led the round with Baxter.
Founded in 2011, VitalConnect has created a wearable biosensor system called VitalPatch that monitors skin temperature, breathing rate,…
